Telitacicept Efficacious, Safe in Treating Rheumatoid Arthritis Patients with Inadequate MTX Response

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.

Related Keywords

Pennsylvania ,United States ,San Diego ,California ,Qing Zuraw ,Remegen Biosciences ,American College Of Rheumatology ,American College Of Rheumatology Convergence ,American College ,Human Recombinant Fusion Protein Targeting ,Neutralizingb Lymphocyte Stimulator ,Proliferation Inducing Ligand ,Rheumatoid Arthritis ,Inadequate Response ,Rheumatology Convergence ,Racr ,Telitacicept ,Mtx ,